...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study
【24h】

A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study

机译:血浆肾素活性配体结合测定质量控制系统:药效学研究中的概念验证

获取原文
获取原文并翻译 | 示例

摘要

While the role of plasma renin activity (PRA) in heart failure has been widely studied in adults, comprehensive data on pediatric heart failure remain lacking. This drawback is increasingly being addressed by academic research. Nevertheless, such pediatric investigations are commonly conducted only once due to ethical constraints. Therefore, the quality of bioanalytical data must be ensured to acquire meaningful insights into maturing humoral parameters. However, appropriate post-validation assessment of bioanalytical runs is currently underrepresented by regulatory guidance. Thus, for applications in an academic environment, an easy-to-handle six-step bioanalytical quality control system was designed based on regulatory guidelines (e.g. U.S. Food and Drug Administration) combined with international recommendations (e.g. Clinical and Laboratory Standards Institute) and current scientific discussion. Its applicability to an enzyme-linked immunosorbent assay for determination of PRA was investigated within three pediatric trials of the EU-funded "Labeling of Enalapril in Neonates up to Adolescents" project. This quality control system identified 15 % bioanalytical runs as non-compliant to the predefined specifications and ensured the reliable quantification of 940 pharmacodynamic samples. The inter-run assessment of quality controls was able to demonstrate the comparability of the study results. Furthermore, 86% of incurred sample reanalysis pairs complied with regulatory requirements (>67 %), thus underlining the long-term reproducibility of the utilized ligand-binding assay. Successful participation in interlaboratory testing confirmed the accuracy of the applied method throughout the entire study period. Further investigations showed no notable differences between the five applied lots of the PRA assay. The applicability of this quality control system was proven in an academic environment and ensured reliable results for PRA over the entire 24-month study period. (C) 2019 Elsevier B.V. All rights reserved.
机译:虽然血浆肾素活性(PRA)在心力衰竭中的作用已被广泛研究成年人,但对儿科心力衰竭的综合数据仍然缺乏。学术研究越来越多地解决了这一缺点。然而,由于道德限制,这些儿科调查通常仅进行一次。因此,必须确保生物分析数据的质量以获得有意义的见解,以实现更好的体液参数。但是,对生物分析运行的适当验证后评估目前受到监管指导的代表性不足。因此,对于学术环境中的应用,基于监管指南(例如美国食品和药物管理局)与国际建议(例如临床和实验室标准研究所)和当前相结合的易于处理的六步生物分析质量控制系统科学讨论。其对酶联免疫吸附测定的适用性用于测定PRA的测定,在欧盟资助的“新生儿的丙普利标记为青少年”项目的三个儿科试验中。该质量控制系统确定了15%的生物分析运行,以不符合预定规格,并确保了940个药效动物样品的可靠量化。对质量控制的间歇性评估能够证明研究结果的可比性。此外,86%的诱导样品再分析对符合调节要求(> 67%),从而强调使用的配体结合测定的长期再现性。成功参与互流检测证实了整个研究期间应用方法的准确性。进一步的研究表明,在PRA测定的五种施加的批量之间没有显着差异。在学术环境中证明了这种质量控制系统的适用性,并确保了在整个24个月的研究期间对PRA的可靠业绩。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号